SI1511770T1 - Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni - Google Patents

Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni

Info

Publication number
SI1511770T1
SI1511770T1 SI200330640T SI200330640T SI1511770T1 SI 1511770 T1 SI1511770 T1 SI 1511770T1 SI 200330640 T SI200330640 T SI 200330640T SI 200330640 T SI200330640 T SI 200330640T SI 1511770 T1 SI1511770 T1 SI 1511770T1
Authority
SI
Slovenia
Prior art keywords
fusion protein
glycoprotein
treatment
vascular diseases
provides
Prior art date
Application number
SI200330640T
Other languages
English (en)
Slovenian (sl)
Inventor
Steffen Massberg
Meinrad Gawaz
Andreas Bueltmann
Goetz Muench
Martin Ungerer
Mario Peluso
Original Assignee
Trigen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigen Gmbh filed Critical Trigen Gmbh
Publication of SI1511770T1 publication Critical patent/SI1511770T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
SI200330640T 2002-06-07 2003-06-05 Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni SI1511770T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02012742A EP1369128A1 (en) 2002-06-07 2002-06-07 Inhibitors of glycoprotein VI and their therapeutic use
PCT/EP2003/005929 WO2003104282A2 (en) 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein vi domain
EP03735562A EP1511770B1 (en) 2002-06-07 2003-06-05 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases

Publications (1)

Publication Number Publication Date
SI1511770T1 true SI1511770T1 (sl) 2007-04-30

Family

ID=29433140

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200330640T SI1511770T1 (sl) 2002-06-07 2003-06-05 Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni

Country Status (13)

Country Link
US (1) US7514543B2 (OSRAM)
EP (4) EP1369128A1 (OSRAM)
JP (1) JP4722480B2 (OSRAM)
CN (1) CN1668721B (OSRAM)
AT (1) ATE346095T1 (OSRAM)
AU (2) AU2003250825A1 (OSRAM)
CA (1) CA2488630C (OSRAM)
DE (1) DE60309865T2 (OSRAM)
DK (1) DK1860118T3 (OSRAM)
ES (2) ES2527717T3 (OSRAM)
SI (1) SI1511770T1 (OSRAM)
WO (2) WO2003104282A2 (OSRAM)
ZA (1) ZA200409776B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
AU2005243193B2 (en) * 2004-04-29 2011-01-27 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein VI and methods of producing these antibodies
ES2534288T3 (es) 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
EP1824979A2 (en) * 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
CA2606450A1 (en) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US20110045504A1 (en) * 2005-12-22 2011-02-24 Noriaki Kume Prognostic Prediction Method for Acute Coronary Syndrome
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
EP2352815B1 (en) * 2008-12-04 2016-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing platelets
EP4311863A3 (en) * 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
WO2014098242A1 (ja) * 2012-12-20 2014-06-26 藤森工業株式会社 血小板凝集能の総合的評価方法
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US11858962B2 (en) * 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
CA2372515C (en) 1999-05-07 2015-12-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP2070939B1 (en) 2001-05-25 2014-04-02 Duke University Modulators of pharmacological agents
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
US7531178B2 (en) * 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
CA2488630C (en) 2011-07-05
WO2003104282A8 (en) 2004-04-29
EP1511770A2 (en) 2005-03-09
WO2003103662A2 (en) 2003-12-18
JP2006512894A (ja) 2006-04-20
AU2003250825A8 (en) 2003-12-22
EP1860118B1 (en) 2014-12-31
DE60309865T2 (de) 2007-10-18
WO2003104282A3 (en) 2004-10-14
ES2276078T3 (es) 2007-06-16
JP4722480B2 (ja) 2011-07-13
ATE346095T1 (de) 2006-12-15
CA2488630A1 (en) 2003-12-18
US7514543B2 (en) 2009-04-07
US20050079541A1 (en) 2005-04-14
CN1668721B (zh) 2012-11-14
AU2003236704A1 (en) 2003-12-22
AU2003236704B2 (en) 2010-07-08
EP1511480A2 (en) 2005-03-09
EP1860118A2 (en) 2007-11-28
EP1860118A3 (en) 2008-07-30
EP1511770B1 (en) 2006-11-22
DK1860118T3 (en) 2015-02-09
AU2003250825A1 (en) 2003-12-22
WO2003104282A2 (en) 2003-12-18
WO2003103662A3 (en) 2004-11-04
ZA200409776B (en) 2007-02-28
DE60309865D1 (de) 2007-01-04
EP1369128A1 (en) 2003-12-10
ES2527717T3 (es) 2015-01-28
CN1668721A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
DE60309865D1 (de) Glycoprotein vi - fc fusions protein zur behandlung von gefässerkrankungen
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
ATE496063T1 (de) Hybrid und tandemproteine von neisseria sp
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
ATE455554T1 (de) Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
SI1873166T1 (sl) IZBOLJĹ ANI sgp 130Fc DIMERJI
DE69733773D1 (de) Fas ANTIGEN-DERIVATE
PL350417A1 (en) Vascular adhesion molecules and modulation of their function
ATE260977T1 (de) Immunoglobulin-bindende proteine
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
WO2003057719A3 (en) Methods of modulating localization and physiological function of ip3 receptors
ATE309351T1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
ATE414164T1 (de) Verfahren zur kontrolle der spaltung mit ompt protease
ATE367438T1 (de) Verfahren zur steigerung der expression von menschlichen tnf-rezeptor
WO2007052067A3 (en) Von willebrand factor (vwf) binding peptides
EP1467207A4 (en) Screening method
DE69810724D1 (de) Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC)
ATE525396T1 (de) Slo2 und slo4, neue kaliumkanal-proteine aus menschlichem gehirn
NZ501161A (en) Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.
ATE529437T1 (de) Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase